Avanir Pharmaceuticals (AVNR) Inactive 10-Q2008 Q1 Quarterly report

Filed: 8 Feb 08, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accrual, allege, appeal, ARB, attaining, attention, atypical, Bausch, bid, biopharmaceutical, biotech, biotechnology, calling, carryforward, challenged, chemical, claim, competitor, confidence, constant, copy, coupled, coupon, court, defense, delisted, delisting, Denmark, depressed, dispute, disputed, divert, DM, dosage, encountered, enforceability, enforcement, entirety, entity, Error, escalating, evolving, Finland, formal, FSP, fundamental, Good, Greece, GSK, Hatch, indemnification, indemnify, infringe, infringing, instrument, introduce, introduction, Israel, Japan, Japanese, jeopardize, justify, knowledge, Kobayashi, Korea, likelihood, listed, listing, Lomb, meaningful, NE, necessitate, network, nonfinancial, Norway, organizational, ownership, Pharmco, Poland, Portugal, prevail, prosecution, prudent, Puerto, rapid, rationale, relevance, relevant, renewal, repaid, restoration, Rico, Room, SB, Spain, stop, Street, superior, supplier, Supreme, surrendering, Sweden, taxation, tier, TM, Trademark, transparency, unanticipated, unfavorably, unrealized, unsuccessful, unutilized, variance, visiting, Washington, Waxman, withholding, Zenviaand, Zenviafor, Zenviain, ZenviaTM

Removed: absorb, accumulate, accumulated, Acquiree, adjusted, aggregating, allocation, AmeriSourceBergen, analyzing, APIC, Applicability, approach, assembled, assume, burdened, capitalized, Cardinal, ceased, choice, CIMA, comparing, comparison, conducted, consummated, context, DCF, defray, denial, discount, discounted, DuraSolv, elimination, equipment, establish, expiring, expressed, external, Finally, forma, fourth, headcount, IEED, insolvency, label, longest, McKesson, merger, modified, OraSolv, oversight, pool, preferable, preliminary, prescribed, pro, production, protect, receiving, record, registry, represented, requisite, residual, retrospectively, run, shorter, simplified, slightly, software, spending, subordinated, supply, unrestricted, window, workforce

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

AVNR similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATION PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)

In connection with the accompanying Quarterly Report ofAvanir Pharmaceuticals (the “Company”) on Form 10-Q for the fiscal quarter ended December 31, 2007 (the “Report”), I, Keith A. Katkin, as Chief Executive Officer of the Company, and Christine G. Ocampo, as Corporate Controller of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Dated: February 8, 2008	/s/ Keith A. Katkin
	Keith A. Katkin
	President and Chief Executive Officer [Principal Executive Officer]


Dated: February 8, 2008	/s/ Christine G. Ocampo
	Christine G. Ocampo
	Corporate Controller [Principal Financial and Accounting Officer]